CTX001 — Competitive Intelligence Brief

CTX001 (CTX001) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CAR-T cell therapy / Gene-edited T-cell therapy. Area: Oncology / Hematologic Malignancies.

phase 3 CAR-T cell therapy / Gene-edited T-cell therapy BCMA (B-cell maturation antigen) / Tumor-associated antigens Oncology / Hematologic Malignancies Biologic

Target snapshot

CTX001 (CTX001) — Vertex Pharmaceuticals Incorporated. CTX001 is a genetically modified T-cell therapy that enhances patient immune cells to recognize and destroy cancer cells expressing specific antigens.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CTX001 TARGET	CTX001	Vertex Pharmaceuticals Incorporated	phase 3	CAR-T cell therapy / Gene-edited T-cell therapy	BCMA (B-cell maturation antigen) / Tumor-associated antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CAR-T cell therapy / Gene-edited T-cell therapy class)

1. Vertex Pharmaceuticals Incorporated · 1 drug in this class